pantoprazole has been researched along with Hematochezia in 77 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Hematochezia: The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Little is known about the efficacy of H(2)-receptor antagonists in preventing recurrence of aspirin-related peptic ulcers." | 9.14 | Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010) |
| "It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin." | 9.14 | Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010) |
| "Proton pump inhibitors (PPIs) are highly effective drugs for patients suffering from peptic ulcer and gastro-esophageal reflux diseases, but recent studies have indicated possible risks with the long-term use of PPIs, such as osteoporosis, fractures, increased risk of pneumonia, diarrhea, iron and vitamin B12 deficiencies." | 5.42 | Pantoprazole-induced thrombocytopenia in patients with upper gastrointestinal bleeding. ( Akbal, E; Aşık, M; Binnetoğlu, E; Bozkurt, N; Erbağ, G; Güneş, F; Şen, H; Tekin, M; Tekin, SZ; Uludağ, A, 2015) |
| "Little is known about the efficacy of H(2)-receptor antagonists in preventing recurrence of aspirin-related peptic ulcers." | 5.14 | Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. ( Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC, 2010) |
| "It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin." | 5.14 | Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010) |
| " PPIs are the mainstay therapeutic agents for prophylaxis against aspirin gastropathy and for acid-related disorders including gastroesophageal reflux disease." | 4.95 | East Asian perspective on the interaction between proton pump inhibitors and clopidogrel. ( Goh, KL; Zou, D, 2017) |
| " Key search terms included pantoprazole, omeprazole, proton-pump inhibitors, gastrointestinal hemorrhage, histamine(2)-receptor antagonists, ranitidine, and cimetidine." | 4.82 | Intravenous proton-pump inhibitors versus H2-antagonists for treatment of GI bleeding. ( Huggins, RM; Latour, JK; Scates, AC, 2003) |
| " We aimed to prospectively compare the effects of continuous infusion and intermittent dosing with pantoprazole on preventing gastric ESD-related bleeding." | 2.90 | Continuous Infusion versus Intermittent Dosing with Pantoprazole for Gastric Endoscopic Submucosal Dissection. ( Baek, DH; Jeon, HK; Kim, DU; Kim, GH; Lee, BE; Seo, JH; Song, GA, 2019) |
| " These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies." | 2.90 | Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. ( Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Bruns, NC; Commerford, PJ; Connolly, SJ; Dagenais, GR; Dans, AL; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, TJ; Hart, RG; Hori, M; Kakkar, AK; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, KP; Moayyedi, P; Muehlhofer, E; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J, 2019) |
| " However, effective dosing or scheduling of proton pump inhibitors for the prevention of delayed bleeding after endoscopic resection remains unclear." | 2.84 | Standard and double-dose intravenous proton pump inhibitor injections for prevention of bleeding after endoscopic resection. ( Choe, JW; Hyun, JJ; Jung, SW; Jung, YK; Kim, SY; Koo, JS; Lee, SW; Yim, HJ, 2017) |
| "Pantoprazole treatment does not impair the efficacy of dual antiplatelet therapy in patients with SAP after PCI." | 2.77 | Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. ( Chmiel, A; Gąsior, Z; Gieszczyk, K; Haberka, M; Kunecki, M; Kyrcz-Krzemień, S; Lasota, B; Mizia, M; Mizia-Stec, K; Najda, J, 2012) |
| "Aspirin was discontinued and pantoprazole was started, with resolution of the bleeding." | 2.49 | Reinitiating aspirin therapy for primary prevention of cardiovascular events in a patient post-aspirin-induced upper gastrointestinal bleed: a case report and review of literature. ( Adly, G; Plakogiannis, R, 2013) |
| " Intravenous pantoprazole is especially distinguished in its lack of clinically relevant drug interactions, and it requires no dosage adjustment for patients with renal insufficiency or with mild to moderate hepatic dysfunction." | 2.41 | Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. ( Metz, DC, 2000) |
| " Another advantage over the histamine 2 receptor antagonists is that pantoprazole does not require dosage adjustment in patients with renal impairment." | 2.41 | Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression. ( Trépanier, EF, 2000) |
| " This suggests that for stress ulcer prophylaxis, intermittent dosing with an intravenous proton pump inhibitor may be an alternative to high-dose continuous infusions of a histamine-2-receptor antagonist." | 2.41 | Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit. ( Steinberg, KP, 2002) |
| " Long-term use is the main factor, but there are a few articles stating that it may also emerge with short-term use." | 1.48 | Short-Term Effect of High-Dose Pantoprazol on Serum and Urinary Magnesium Levels. ( Bostan, F; Cekin, AH; Dolu, S; Ellidag, HY; Kok, M; Sahinturk, Y; Uyar, S; Yolcular, BO, 2018) |
| "Proton pump inhibitors (PPIs) are highly effective drugs for patients suffering from peptic ulcer and gastro-esophageal reflux diseases, but recent studies have indicated possible risks with the long-term use of PPIs, such as osteoporosis, fractures, increased risk of pneumonia, diarrhea, iron and vitamin B12 deficiencies." | 1.42 | Pantoprazole-induced thrombocytopenia in patients with upper gastrointestinal bleeding. ( Akbal, E; Aşık, M; Binnetoğlu, E; Bozkurt, N; Erbağ, G; Güneş, F; Şen, H; Tekin, M; Tekin, SZ; Uludağ, A, 2015) |
| "Epiphrenic diverticula are outpouchings of the esophagus that retain some or all layers of the esophageal wall." | 1.37 | Massive upper gastrointestinal bleed from epiphrenic diverticulum. ( Burgos, JD; Dias, A; Garcia, CJ; Hejazi, RA; Huerta, A; Zuckerman, MJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 28 (36.36) | 29.6817 |
| 2010's | 40 (51.95) | 24.3611 |
| 2020's | 9 (11.69) | 2.80 |
| Authors | Studies |
|---|---|
| Halling, CMB | 1 |
| Møller, MH | 8 |
| Marker, S | 8 |
| Krag, M | 6 |
| Kjellberg, J | 1 |
| Perner, A | 8 |
| Gyrd-Hansen, D | 1 |
| Zhu, Y | 1 |
| Wang, X | 1 |
| Yang, Y | 1 |
| Liu, L | 1 |
| Zhao, Q | 1 |
| Yu, L | 1 |
| Dennis, BB | 1 |
| Thabane, L | 4 |
| Heels-Ansdell, D | 3 |
| Dionne, JC | 1 |
| Binnie, A | 1 |
| Tsang, J | 1 |
| Guyatt, G | 4 |
| Ahmed, A | 1 |
| Lauzier, F | 4 |
| Deane, A | 2 |
| Arabi, Y | 3 |
| Marshall, J | 2 |
| Zytaruk, N | 4 |
| Saunders, L | 3 |
| Finfer, S | 4 |
| Myburgh, J | 3 |
| Muscedere, J | 4 |
| English, S | 3 |
| Ostermann, M | 3 |
| Hardie, M | 3 |
| Knowles, S | 3 |
| Cook, D | 3 |
| Deane, AM | 3 |
| Alhazzani, W | 4 |
| Marshall, JC | 2 |
| Chapman, MJ | 2 |
| Venkatesh, B | 2 |
| Young, P | 2 |
| Billot, L | 2 |
| Al-Fares, AA | 1 |
| Hammond, NE | 1 |
| Hall, R | 3 |
| Rajbhandari, D | 1 |
| Poole, A | 2 |
| Johnson, D | 1 |
| Iqbal, M | 1 |
| Reis, G | 1 |
| Xie, F | 2 |
| Cook, DJ | 1 |
| Hammond, N | 1 |
| Al-Fares, A | 1 |
| Schefold, JC | 3 |
| Wetterslev, J | 3 |
| Wise, MP | 3 |
| Borthwick, M | 3 |
| Bendel, S | 3 |
| Keus, F | 3 |
| Guttormsen, AB | 3 |
| Lange, T | 3 |
| Morare, NMT | 1 |
| Bosman, C | 1 |
| Ogunrombi, AB | 1 |
| Gündoğan, K | 1 |
| Karakoc, E | 1 |
| Teke, T | 1 |
| Zerman, A | 1 |
| Esmaoglu, A | 1 |
| Temel, Ş | 1 |
| Güven, M | 1 |
| Sungur, M | 1 |
| Kofoed, A | 1 |
| Haase, N | 2 |
| Holst, LB | 2 |
| Granholm, A | 4 |
| Callaway, K | 1 |
| Lakkad, M | 1 |
| Painter, JT | 1 |
| Dayer, L | 1 |
| Oswalt, AK | 1 |
| Alshahrani, M | 1 |
| English, SW | 1 |
| Arabi, YM | 1 |
| Karachi, T | 1 |
| Rochwerg, B | 1 |
| Daneman, N | 1 |
| Alshamsi, F | 1 |
| Heel-Ansdell, D | 1 |
| El-Kersh, K | 1 |
| Jalil, B | 1 |
| McClave, SA | 1 |
| Cavallazzi, R | 1 |
| Guardiola, J | 1 |
| Guilkey, K | 1 |
| Persaud, AK | 1 |
| Furmanek, SP | 1 |
| Guinn, BE | 1 |
| Wiemken, TL | 1 |
| Alhariri, BC | 1 |
| Kellie, SP | 1 |
| Saad, M | 1 |
| Uyar, S | 1 |
| Dolu, S | 1 |
| Yolcular, BO | 1 |
| Ellidag, HY | 1 |
| Kok, M | 1 |
| Bostan, F | 1 |
| Sahinturk, Y | 1 |
| Cekin, AH | 1 |
| Rattanasupar, A | 1 |
| Sengmanee, S | 1 |
| Mesquita, WJ | 1 |
| Kline, CM | 1 |
| Vernier, P | 1 |
| Ledgerwood, AM | 1 |
| Lucas, CE | 1 |
| Barkun, A | 2 |
| Bardou, M | 3 |
| Rasmussen, BS | 2 |
| Siegemund, M | 1 |
| Bundgaard, H | 1 |
| Elkmann, T | 2 |
| Jensen, JV | 1 |
| Nielsen, RD | 1 |
| Liboriussen, L | 1 |
| Bestle, MH | 1 |
| Elkjær, JM | 1 |
| Palmqvist, DF | 1 |
| Bäcklund, M | 1 |
| Laake, JH | 2 |
| Bådstøløkken, PM | 1 |
| Grönlund, J | 1 |
| Breum, O | 1 |
| Walli, A | 1 |
| Winding, R | 1 |
| Iversen, S | 1 |
| Jarnvig, IL | 1 |
| White, JO | 1 |
| Brand, B | 1 |
| Madsen, MB | 1 |
| Quist, L | 1 |
| Thornberg, KJ | 1 |
| Møller, A | 1 |
| Wiis, J | 1 |
| Anthon, CT | 1 |
| Meyhoff, TS | 1 |
| Hjortrup, PB | 2 |
| Aagaard, SR | 1 |
| Andreasen, JB | 1 |
| Sørensen, CA | 1 |
| Haure, P | 1 |
| Hauge, J | 1 |
| Hollinger, A | 1 |
| Scheuzger, J | 1 |
| Tuchscherer, D | 1 |
| Vuilliomenet, T | 1 |
| Takala, J | 1 |
| Jakob, SM | 1 |
| Vang, ML | 1 |
| Pælestik, KB | 1 |
| Andersen, KLD | 1 |
| van der Horst, ICC | 1 |
| Dieperink, W | 1 |
| Fjølner, J | 1 |
| Kjer, CKW | 1 |
| Sølling, C | 1 |
| Sølling, CG | 1 |
| Karttunen, J | 1 |
| Morgan, MPG | 1 |
| Sjøbø, B | 1 |
| Engstrøm, J | 1 |
| Agerholm-Larsen, B | 1 |
| Lee, BE | 1 |
| Kim, GH | 2 |
| Song, GA | 2 |
| Seo, JH | 1 |
| Jeon, HK | 1 |
| Baek, DH | 1 |
| Kim, DU | 1 |
| Quenot, JP | 1 |
| Dargent, A | 1 |
| He, N | 1 |
| Yan, Y | 1 |
| Zhai, S | 1 |
| Tan, MC | 1 |
| Tansel, A | 1 |
| Graham, DY | 1 |
| Widmer, AF | 1 |
| Götz, M | 1 |
| Nitschmann, S | 1 |
| Moayyedi, P | 2 |
| Eikelboom, JW | 2 |
| Bosch, J | 2 |
| Connolly, SJ | 2 |
| Dyal, L | 2 |
| Shestakovska, O | 2 |
| Leong, D | 2 |
| Anand, SS | 2 |
| Störk, S | 2 |
| Branch, KRH | 2 |
| Bhatt, DL | 2 |
| Verhamme, PB | 2 |
| O'Donnell, M | 2 |
| Maggioni, AP | 2 |
| Lonn, EM | 2 |
| Piegas, LS | 2 |
| Ertl, G | 2 |
| Keltai, M | 2 |
| Cook Bruns, N | 1 |
| Muehlhofer, E | 2 |
| Dagenais, GR | 2 |
| Kim, JH | 2 |
| Hori, M | 2 |
| Steg, PG | 2 |
| Hart, RG | 2 |
| Diaz, R | 2 |
| Alings, M | 2 |
| Widimsky, P | 2 |
| Avezum, A | 2 |
| Probstfield, J | 2 |
| Zhu, J | 2 |
| Liang, Y | 2 |
| Lopez-Jaramillo, P | 2 |
| Kakkar, A | 1 |
| Parkhomenko, AN | 2 |
| Ryden, L | 2 |
| Pogosova, N | 2 |
| Dans, A | 1 |
| Lanas, F | 2 |
| Commerford, PJ | 2 |
| Torp-Pedersen, C | 2 |
| Guzik, T | 1 |
| Vinereanu, D | 2 |
| Tonkin, AM | 2 |
| Lewis, BS | 2 |
| Felix, C | 2 |
| Yusoff, K | 2 |
| Metsarinne, K | 1 |
| Fox, KAA | 2 |
| Yusuf, S | 2 |
| Bruns, NC | 1 |
| Kakkar, AK | 1 |
| Dans, AL | 1 |
| Guzik, TJ | 1 |
| Metsarinne, KP | 1 |
| Collet, MO | 1 |
| Jensen, AKG | 1 |
| Bestle, M | 1 |
| Arenkiel, B | 1 |
| Kamper, MK | 1 |
| Lång, M | 1 |
| Pawlowicz-Dworzanska, MB | 1 |
| Karlsson, S | 1 |
| Liisanantti, J | 1 |
| Dey, N | 1 |
| Knudsen, H | 1 |
| Korkmaz, U | 1 |
| Alcelik, A | 1 |
| Eroglu, M | 1 |
| Korkmaz, AN | 1 |
| Aktas, G | 1 |
| Binnetoğlu, E | 1 |
| Akbal, E | 1 |
| Şen, H | 1 |
| Güneş, F | 1 |
| Erbağ, G | 1 |
| Aşık, M | 1 |
| Bozkurt, N | 1 |
| Uludağ, A | 1 |
| Tekin, M | 1 |
| Tekin, SZ | 1 |
| Baeg, MK | 1 |
| Choi, MG | 1 |
| Moon, SJ | 1 |
| Lim, CH | 1 |
| Kim, JS | 1 |
| Cho, YK | 1 |
| Park, JM | 1 |
| Lee, IS | 1 |
| Kim, SW | 1 |
| Choi, KY | 1 |
| Choi, CW | 2 |
| Kang, DH | 2 |
| Kim, HW | 2 |
| Hong, JB | 1 |
| Park, SB | 2 |
| Kim, SJ | 1 |
| Cho, M | 2 |
| Yao, DK | 1 |
| Chen, H | 1 |
| Wang, L | 1 |
| Li, HW | 1 |
| Wang, LX | 1 |
| Selvanderan, SP | 1 |
| Summers, MJ | 1 |
| Finnis, ME | 1 |
| Plummer, MP | 1 |
| Ali Abdelhamid, Y | 1 |
| Anderson, MB | 1 |
| Rayner, CK | 1 |
| Jung, SW | 1 |
| Kim, SY | 1 |
| Choe, JW | 1 |
| Hyun, JJ | 1 |
| Jung, YK | 1 |
| Koo, JS | 1 |
| Yim, HJ | 1 |
| Lee, SW | 1 |
| Zou, D | 1 |
| Goh, KL | 1 |
| Boo, GB | 1 |
| Oh, JC | 1 |
| Lee, BJ | 1 |
| Lee, DM | 1 |
| Kim, YD | 1 |
| Park, CG | 1 |
| Kim, MW | 1 |
| Tsai, JJ | 1 |
| Lin, HJ | 2 |
| Alaniz, C | 1 |
| Mohammad, RA | 1 |
| Welage, LS | 2 |
| van Werkum, JW | 1 |
| ten Berg, JM | 1 |
| Bredenoord, AJ | 1 |
| Ng, FH | 1 |
| Wong, SY | 1 |
| Lam, KF | 1 |
| Chu, WM | 1 |
| Chan, P | 1 |
| Ling, YH | 1 |
| Kng, C | 1 |
| Yuen, WC | 1 |
| Lau, YK | 1 |
| Kwan, A | 1 |
| Wong, BC | 1 |
| Bretagne, JF | 1 |
| Sung, JJ | 1 |
| Lau, JY | 1 |
| Ching, JY | 1 |
| Wu, JC | 1 |
| Lee, YT | 1 |
| Chiu, PW | 1 |
| Leung, VK | 1 |
| Wong, VW | 1 |
| Chan, FK | 1 |
| Craig, DG | 1 |
| Thimappa, R | 1 |
| Anand, V | 1 |
| Sebastian, S | 1 |
| Wu, H | 1 |
| Jing, Q | 1 |
| Wang, J | 1 |
| Guo, X | 1 |
| Juurlink, DN | 1 |
| Garcia, CJ | 1 |
| Dias, A | 1 |
| Hejazi, RA | 1 |
| Burgos, JD | 1 |
| Huerta, A | 1 |
| Zuckerman, MJ | 1 |
| Park, KT | 1 |
| Mizia-Stec, K | 1 |
| Haberka, M | 1 |
| Mizia, M | 1 |
| Lasota, B | 1 |
| Kunecki, M | 1 |
| Gieszczyk, K | 1 |
| Chmiel, A | 1 |
| Najda, J | 1 |
| Kyrcz-Krzemień, S | 1 |
| Gąsior, Z | 1 |
| Altay, S | 1 |
| Cakmak, HA | 1 |
| Boz, GC | 1 |
| Koca, S | 1 |
| Velibey, Y | 1 |
| Lo, GH | 1 |
| Perng, DS | 1 |
| Chang, CY | 1 |
| Tai, CM | 1 |
| Wang, HM | 1 |
| Lin, HC | 1 |
| Adly, G | 1 |
| Plakogiannis, R | 1 |
| Huggins, RM | 1 |
| Scates, AC | 1 |
| Latour, JK | 1 |
| Pisegna, JR | 2 |
| Pais, SA | 1 |
| Yang, R | 1 |
| van Rensburg, CJ | 1 |
| Hartmann, M | 1 |
| Thorpe, A | 1 |
| Venter, L | 1 |
| Theron, I | 1 |
| Lühmann, R | 1 |
| Wurst, W | 1 |
| Maltz, C | 1 |
| Enns, R | 1 |
| Andrews, CN | 1 |
| Fishman, M | 1 |
| Hahn, M | 1 |
| Atkinson, K | 1 |
| Kwan, P | 1 |
| Levy, A | 1 |
| Shaheen, NJ | 1 |
| Stuart, E | 1 |
| Schmitz, SM | 1 |
| Mitchell, KL | 1 |
| Fried, MW | 1 |
| Zacks, S | 1 |
| Russo, MW | 1 |
| Galanko, J | 1 |
| Shrestha, R | 1 |
| Thalmann, M | 1 |
| Sodeck, GH | 1 |
| Kavouras, S | 1 |
| Matalas, A | 1 |
| Skenderi, K | 1 |
| Yannikouris, N | 1 |
| Domanovits, H | 1 |
| Keyvani, L | 1 |
| Murthy, S | 1 |
| Leeson, S | 1 |
| Targownik, LE | 1 |
| Yilmaz, S | 1 |
| Bayan, K | 1 |
| Dursun, M | 1 |
| Canoruç, F | 1 |
| Kilinç, N | 1 |
| Tüzün, Y | 1 |
| Daniş, R | 1 |
| Ertem, M | 1 |
| Dahshan, A | 1 |
| Bajaj, JS | 1 |
| Dua, KS | 1 |
| Hanson, K | 1 |
| Presberg, K | 1 |
| Jeong, HK | 1 |
| Park, CH | 1 |
| Jun, CH | 1 |
| Lee, GH | 1 |
| Kim, HI | 1 |
| Kim, HS | 1 |
| Choi, SK | 1 |
| Rew, JS | 1 |
| Al-Sabah, S | 1 |
| Barkun, AN | 1 |
| Herba, K | 1 |
| Adam, V | 1 |
| Fallone, C | 1 |
| Mayrand, S | 1 |
| Pomier-Layrargues, G | 1 |
| Kennedy, W | 1 |
| Somberg, L | 1 |
| Morris, J | 1 |
| Fantus, R | 1 |
| Graepel, J | 1 |
| Field, BG | 1 |
| Lynn, R | 1 |
| Karlstadt, R | 1 |
| Metz, DC | 1 |
| Trépanier, EF | 1 |
| Tang, SJ | 1 |
| Nieto, JM | 1 |
| Jensen, DM | 1 |
| Ohning, GV | 1 |
| Wolfe, MM | 1 |
| Sachs, G | 1 |
| Steinberg, KP | 1 |
| Morgan, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU)[NCT02467621] | Phase 4 | 3,350 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Evaluation of the Efficacy of Different Duration of a Proton Pump Inhibitor in the Prevention of Upper Gastrointestinal Mucosal Injury in Patients Taking 12-month Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting[NCT03908593] | Phase 4 | 232 participants (Anticipated) | Interventional | 2019-10-14 | Active, not recruiting | ||
| Sup-Icu RENal (SIREN) - a Sub-analysis of the Prospective SUP (Stress Ulcer Prophylaxis)-ICU Trial on the Risk of GI- Bleeding in ICU Patients Receiving Renal Replacement Therapy[NCT02718261] | Phase 4 | 3,350 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Cuff Leak Test and Airway Obstruction in Mechanically Ventilated ICU Patients Pilot Trial[NCT03372707] | 100 participants (Actual) | Interventional | 2018-07-05 | Completed | |||
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| The Efficacy and Safety of Proton Pump Inhibitor ( in Patients With Moderate Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary: A Randomised, Open ,Compared With Control[NCT05820048] | Phase 4 | 300 participants (Anticipated) | Interventional | 2023-05-01 | Not yet recruiting | ||
| Delirium Screening 3 Methods Study (DELIS-3). Agreement Between CAM-ICU, CAM-ICU-7 and ICDSC in a Danish Population of ICU Patients and Nurses' Perception of the Clinical Relevance of Delirium Screening[NCT04551508] | 1,126 participants (Actual) | Observational | 2020-09-09 | Completed | |||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| [NCT00153725] | 156 participants | Interventional | 2003-02-28 | Completed | |||
| Institute of Emergency and Critical Care Medicine , School of Yang-Ming University[NCT01588886] | 9,000 participants (Actual) | Observational | 2012-03-31 | Completed | |||
| A Randomized, Controlled Trial of Ligation Plus Vasoconstrictor vs.Ligation Plus Proton Pump Inhibitor in the Control of Acute Esophageal Variceal Bleeding[NCT01112852] | Phase 4 | 118 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Comparative Effectiveness Research: Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails to Treat the Patients With Acute Variceal Bleeding[NCT02311608] | 1,320 participants (Anticipated) | Observational | 2014-02-28 | Recruiting | |||
| Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery[NCT00839488] | Phase 4 | 6 participants (Actual) | Interventional | 2008-04-30 | Terminated (stopped due to the chief of GS left the hopsital and the successor did't want to keep on this study) | ||
| Laparoscopic Revision Gastric Bypass Surgery for Perforated Marginal Ulcer: A 10 Year Experience[NCT01041196] | 30 participants (Actual) | Observational | 2009-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Data for landmark mortality 1 year after randomization. (NCT02467621)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 610 |
| Normal Saline | 601 |
Landmark mortality 90-days after randomization (NCT02467621)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 510 |
| Normal Saline | 499 |
Number of participants with one or more episodes of clinically important GI bleeding in the ICU (NCT02467621)
Timeframe: Until ICU discharge, maximum 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 41 |
| Normal Saline | 69 |
Composite outcome of the number of participants with one or more of the mentioned conditions in the ICU (NCT02467621)
Timeframe: Until ICU discharge, maximum 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 360 |
| Normal Saline | 372 |
Number of participants with one or more episodes of pneumonia or clostridium difficile infection in the ICU (NCT02467621)
Timeframe: Until ICU discharge, maximum 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 276 |
| Normal Saline | 279 |
Serious adverse reactions are: anaphylactic reactions, agranulocytosis, pancytopenia, acute hepatic failure, Steven Johnsons Syndrome and toxic epidermal necrolysis, interstitial nephritis and angioedema. (NCT02467621)
Timeframe: Until ICU discharge, maximum 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Proton Pump Inhibitor (PPI) | 0 |
| Normal Saline | 0 |
Percentage of days alive and free from mechanical ventilation, circulatory support and renal replacement therapy (NCT02467621)
Timeframe: Within 90 days
| Intervention | percentage of days (Number) |
|---|---|
| Proton Pump Inhibitor (PPI) | 92 |
| Normal Saline | 92 |
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
10 reviews available for pantoprazole and Hematochezia
| Article | Year |
|---|---|
East Asian perspective on the interaction between proton pump inhibitors and clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anticoagulants; Asia, Eastern; Asian People; Aspirin; Clopi | 2017 |
[Prevention of GI bleeding due to antiplatelet agents: a labyrinth!].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Comb | 2009 |
Reinitiating aspirin therapy for primary prevention of cardiovascular events in a patient post-aspirin-induced upper gastrointestinal bleed: a case report and review of literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Car | 2013 |
Intravenous proton-pump inhibitors versus H2-antagonists for treatment of GI bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cimetidine; Drug Administration Schedule; E | 2003 |
Treating patients with acute gastrointestinal bleeding or rebleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials a | 2003 |
Diagnostic and therapeutic options in the management of nonvariceal upper gastrointestinal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Diathermy; Endoscopy, Ga | 2003 |
Potential uses of intravenous proton pump inhibitors to control gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Gastric Ac | 2000 |
Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis, Peptic; Gas | 2000 |
Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Critical Illness; Gastric Mucosa; Gastroint | 2002 |
Intravenous proton pump inhibitors in the critical care setting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Canada; Critical Care; Gastrointestinal Hem | 2002 |
34 trials available for pantoprazole and Hematochezia
| Article | Year |
|---|---|
The effects of pantoprazole vs. placebo on 1-year outcomes, resource use and employment status in ICU patients at risk for gastrointestinal bleeding: a secondary analysis of the SUP-ICU trial.
Topics: Employment; Gastrointestinal Hemorrhage; Humans; Intensive Care Units; Pantoprazole; Peptic Ulcer; P | 2022 |
Proton pump inhibitor in the prevention of upper gastrointestinal mucosal injury associated with dual antiplatelet therapy after coronary artery bypass grafting (DACAB-GI-2): study protocol for a randomized controlled trial.
Topics: Aspirin; Coronary Artery Bypass; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Pan | 2022 |
Proton pump inhibitors in critically ill mechanically ventilated patients with COVID-19: protocol for a substudy of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial.
Topics: Cohort Studies; COVID-19; Critical Illness; Gastrointestinal Hemorrhage; Humans; Pantoprazole; Proto | 2023 |
REVISE:
Topics: Adolescent; Adult; Gastrointestinal Hemorrhage; Humans; Intensive Care Units; Pantoprazole; Pneumoni | 2023 |
REVISE: re-evaluating the inhibition of stress erosions in the ICU-statistical analysis plan for a randomized trial.
Topics: Adolescent; Critical Illness; Gastrointestinal Hemorrhage; Humans; Intensive Care Units; Pantoprazol | 2023 |
Outcomes of Prophylactic Pantoprazole in Adult Intensive Care Unit Patients Receiving Dialysis: Results of a Randomized Trial.
Topics: Acute Kidney Injury; Aged; Clostridium Infections; Critical Care; Cross Infection; Female; Gastroint | 2019 |
Effects of oral/enteral nutrition alone versus plus pantoprazole on gastrointestinal bleeding in critically ill patients with low risk factor: a multicenter, randomized controlled trial
Topics: Aged; Anti-Ulcer Agents; Critical Care; Critical Illness; Enteral Nutrition; Female; Gastrointestina | 2020 |
Effects of simulated sample sizes on the mortality effect estimates in three randomized intensive care unit trials.
Topics: Anti-Ulcer Agents; Computer Simulation; Critical Care; Denmark; Female; Finland; Gastrointestinal He | 2020 |
Predictors of gastrointestinal bleeding in adult ICU patients in the SUP-ICU trial.
Topics: Adult; Gastrointestinal Hemorrhage; Humans; Intensive Care Units; Pantoprazole; Peptic Ulcer; Simpli | 2021 |
Withholding Pantoprazole for Stress Ulcer Prophylaxis in Critically Ill Patients: A Pilot Randomized Clinical Trial and Meta-Analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Clostridium Infections; Critical Illness; Doub | 2017 |
Enteral nutrition as stress ulcer prophylaxis in critically ill patients: A randomized controlled exploratory study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Aged; Anti-Ulcer Agents; Critical Illness; D | 2018 |
Comparison of High Dose and Standard Dose Proton Pump Inhibitor before Endoscopy in Patients with Non-Portal Hypertension Bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Intravenous; Dose-Response Relationship, Dr | 2016 |
Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU.
Topics: Aged; Critical Illness; Female; Gastrointestinal Hemorrhage; Humans; Injections, Intravenous; Intens | 2018 |
Continuous Infusion versus Intermittent Dosing with Pantoprazole for Gastric Endoscopic Submucosal Dissection.
Topics: Aged; Endoscopic Mucosal Resection; Female; Gastrointestinal Hemorrhage; Gastroscopy; Humans; Infusi | 2019 |
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Dose-Response Relation | 2019 |
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Enterocol | 2019 |
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Enterocol | 2019 |
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Enterocol | 2019 |
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Enterocol | 2019 |
Pantoprazole in ICU patients at risk for gastrointestinal bleeding-1-year mortality in the SUP-ICU trial.
Topics: Aged; Anti-Ulcer Agents; Critical Care; Double-Blind Method; Female; Follow-Up Studies; Gastrointest | 2019 |
Preprocedural rabeprazole treatment before endoscopic submucosal dissection for gastric neoplasms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Dissection; Female; Gastric Mucosa; Gastrointestinal | 2014 |
High Dose Proton Pump Inhibitor Infusion Versus Bolus Injection for the Prevention of Bleeding After Endoscopic Submucosal Dissection: Prospective Randomized Controlled Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Dose-Response Relationship, Drug; Drug Administration | 2015 |
Comparison of Intravenous plus Oral Pantoprazole Therapy and Oral Pantoprazole Alone for Preventing Gastrointestinal Bleeding in Acute Coronary Syndrome Patients with High Bleeding Risk.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Administration, Intravenous; Admin | 2015 |
Pantoprazole or Placebo for Stress Ulcer Prophylaxis (POP-UP): Randomized Double-Blind Exploratory Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Clostridium Infections; Double-Blind Method; F | 2016 |
Standard and double-dose intravenous proton pump inhibitor injections for prevention of bleeding after endoscopic resection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Aged; Dose-Response Relationship, Drug; Drug Admin | 2017 |
[The effect of proton pump inhibitor on healing of post-esophageal variceal ligation ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophageal and Gastric Varices; Esophago | 2008 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non- | 2010 |
Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2010 |
Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Age Factors; Aged; Anticoagulants; | 2011 |
Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Cl | 2012 |
Controlled trial of ligation plus vasoconstrictor versus proton pump inhibitor in the control of acute esophageal variceal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Combined Modality Therapy; Esophageal and Gast | 2013 |
Controlled trial of ligation plus vasoconstrictor versus proton pump inhibitor in the control of acute esophageal variceal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Combined Modality Therapy; Esophageal and Gast | 2013 |
Controlled trial of ligation plus vasoconstrictor versus proton pump inhibitor in the control of acute esophageal variceal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Combined Modality Therapy; Esophageal and Gast | 2013 |
Controlled trial of ligation plus vasoconstrictor versus proton pump inhibitor in the control of acute esophageal variceal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Combined Modality Therapy; Esophageal and Gast | 2013 |
Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Double-Blind Method; Esophageal and Gastric | 2005 |
Proton pump inhibition prevents gastrointestinal bleeding in ultramarathon runners: a randomised, double blinded, placebo controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Double-Blind Method; Feces; Female; | 2006 |
Does adding misoprostol to standard intravenous proton pump inhibitor protocol improve the outcome of aspirin/NSAID-induced upper gastrointestinal bleeding?: a randomized prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2007 |
Prospective, randomized trial comparing effect of oral versus intravenous pantoprazole on rebleeding after nonvariceal upper gastrointestinal bleeding: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Anti-Ulcer Agents; Endoscopy, G | 2007 |
A prospective randomized trial of either famotidine or pantoprazole for the prevention of bleeding after endoscopic submucosal dissection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Dissection; Famotidine; Female; Ga | 2007 |
Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cimetidine; Drug Administration S | 2008 |
33 other studies available for pantoprazole and Hematochezia
| Article | Year |
|---|---|
Splenic artery aneurysm as a rare cause of an upper GIT bleed.
Topics: Administration, Intravenous; Aneurysm; Diagnosis, Differential; Embolization, Therapeutic; Esophagos | 2019 |
The Impact of Continuous Infusion Compared to Intravenous Bolus Administration of Pantoprazole on Length of Intensive Care Unit Stay in Critically Ill Patients.
Topics: Adult; Critical Illness; Gastrointestinal Hemorrhage; Humans; Infusions, Intravenous; Intensive Care | 2023 |
Short-Term Effect of High-Dose Pantoprazol on Serum and Urinary Magnesium Levels.
Topics: Dose-Response Relationship, Drug; Female; Gastrointestinal Hemorrhage; Hospitalization; Humans; Hype | 2018 |
Failure of gastric prophylaxis against stress bleeding reflects inadequate pH control.
Topics: Adult; Female; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentra | 2018 |
Proton-Pump Inhibitor Prophylaxis in the ICU - Benefits Worth the Risks?
Topics: Gastrointestinal Hemorrhage; Humans; Intensive Care Units; Pantoprazole; Proton Pump Inhibitors; Pro | 2018 |
Prophylaxis for stress related gastrointestinal bleeding in the ICU: Should we adjust to each patient's individual risk?
Topics: Anti-Ulcer Agents; Critical Care; Gastrointestinal Hemorrhage; Humans; Meta-Analysis as Topic; Panto | 2019 |
Pantoprazole in Patients in the ICU.
Topics: Gastrointestinal Hemorrhage; Humans; Intensive Care Units; Pantoprazole; Proton Pump Inhibitors | 2019 |
Pantoprazole in Patients in the ICU.
Topics: Gastrointestinal Hemorrhage; Humans; Intensive Care Units; Pantoprazole; Proton Pump Inhibitors | 2019 |
Pantoprazole in Patients in the ICU.
Topics: Gastrointestinal Hemorrhage; Humans; Intensive Care Units; Pantoprazole; Proton Pump Inhibitors | 2019 |
Pantoprazole in Patients in the ICU. Reply.
Topics: Gastrointestinal Hemorrhage; Humans; Intensive Care Units; Pantoprazole; Proton Pump Inhibitors | 2019 |
[Prevention of gastrointestinal bleeding by means of proton pump inhibitors].
Topics: Gastrointestinal Hemorrhage; Humans; Intensive Care Units; Pantoprazole; Proton Pump Inhibitors | 2019 |
External validation of the Simplified Mortality Score for the Intensive Care Unit (SMS-ICU).
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Calibration; Cohort Studies; Data Interpretation, | 2019 |
Pantoprazole-induced thrombocytopenia in a patient with upper gastrointestinal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged, 80 and over; Anti-Ulcer Agents; Gastrointestinal Hemo | 2013 |
Pantoprazole-induced thrombocytopenia in patients with upper gastrointestinal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Female; Gastrointestinal Hemorrhage; Humans; M | 2015 |
Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stressed related mucosal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cimetidine; Critical Illness; Gastric Mu | 2008 |
Continuous infusion of pantoprazole with octreotide does not improve management of variceal hemorrhage.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Blood Transfusion; Cohort Studies; Drug | 2009 |
Proton pump inhibitors and clopidogrel: a difficult dilemma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage | 2009 |
Summaries for patients. Benefits and risks of continuing aspirin in patients with peptic ulcer bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2010 |
Inappropriate utilization of intravenous proton pump inhibitors in hospital practice--a prospective study of the extent of the problem and predictive factors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Female; Gastrointestinal Hemorrhage; Hospitals, Teach | 2010 |
Clopidogrel with or without omeprazole in coronary disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cardiovascular Diseases; Chemistry, Pharmaceutical; Clopido | 2011 |
Massive upper gastrointestinal bleed from epiphrenic diverticulum.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged, 80 and over; Diverticulum; Endoscopy, Digestive Syste | 2011 |
Somatostatin adjunctive therapy for non-variceal upper gastrointestinal rebleeding after endoscopic therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Database | 2011 |
Prolonged coagulopathy related to coumarin rodenticide in a young patient: superwarfarin poisoning.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; 4-Hydroxycoumarins; Adult; Animals; Anti-Ulcer Agents; Anti | 2012 |
Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2003 |
Dosage of intravenous pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastrointestinal Hemorrh | 2003 |
Description of prescribing practices in patients with upper gastrointestinal bleeding receiving intravenous proton pump inhibitors: a multicentre evaluation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Aged; Aged, 80 and over; Anti-Ulcer Agents; | 2004 |
Pre-endoscopic proton pump inhibitor therapy reduces recurrent adverse gastrointestinal outcomes in patients with acute non-variceal upper gastrointestinal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Administration, Oral; Aged; Aged, 80 and ove | 2006 |
Pre-endoscopic PPI therapy reduces recurrent adverse outcomes in acute non-variceal upper gastrointestinal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Administration, Oral; Aged; Aged, 80 and ove | 2007 |
Bleeding Meckel diverticulum responds to intravenous pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Gastrointestinal Hemorrhage; Hema | 2007 |
Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Canada; Cost-Benefit Analysis; Decision Trees; Dose-Respons | 2008 |
The novel use of an intravenous proton pump inhibitor in a patient with short bowel syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastrointestinal Hemorrh | 2002 |
Proton pump inhibitors and gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Gastric Acid; Gastrointe | 2001 |
Pantoprazole IV (Protonix IV).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clinical Trials as Topic; Drug Approval; Fe | 2002 |